JPH08512019A - 免疫反応剤およびキレート化された放射性核種からなるl−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング - Google Patents

免疫反応剤およびキレート化された放射性核種からなるl−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング

Info

Publication number
JPH08512019A
JPH08512019A JP6520313A JP52031394A JPH08512019A JP H08512019 A JPH08512019 A JP H08512019A JP 6520313 A JP6520313 A JP 6520313A JP 52031394 A JP52031394 A JP 52031394A JP H08512019 A JPH08512019 A JP H08512019A
Authority
JP
Japan
Prior art keywords
residue
enantiomeric
precursor
group
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6520313A
Other languages
English (en)
Japanese (ja)
Inventor
スノー、ロバート・アレン
ブラック、クリストファー・ダグラス・バリアント
Original Assignee
ザ・ウエルカム・ファウンデーション・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ウエルカム・ファウンデーション・リミテッド filed Critical ザ・ウエルカム・ファウンデーション・リミテッド
Publication of JPH08512019A publication Critical patent/JPH08512019A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP6520313A 1993-03-10 1994-03-10 免疫反応剤およびキレート化された放射性核種からなるl−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング Pending JPH08512019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3308393A 1993-03-10 1993-03-10
US08/033,083 1993-03-10
PCT/US1994/002610 WO1994020523A1 (en) 1993-03-10 1994-03-10 Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides

Publications (1)

Publication Number Publication Date
JPH08512019A true JPH08512019A (ja) 1996-12-17

Family

ID=21868470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6520313A Pending JPH08512019A (ja) 1993-03-10 1994-03-10 免疫反応剤およびキレート化された放射性核種からなるl−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング

Country Status (5)

Country Link
EP (1) EP0691981A1 (de)
JP (1) JPH08512019A (de)
AU (1) AU6402594A (de)
CA (1) CA2157902A1 (de)
WO (1) WO1994020523A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512978A (ja) * 2001-10-26 2005-05-12 ノクゾン ファルマ アーゲー 修飾l−核酸

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203168T1 (de) * 1992-05-07 2001-08-15 Nycomed Imaging As Komplexbildnermittel und zielimmunoreagenzien
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6395716B1 (en) * 1998-08-10 2002-05-28 Novirio Pharmaceuticals Limited β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
ATE452655T1 (de) * 2001-06-10 2010-01-15 Noxxon Pharma Ag Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
EP1288309A1 (de) * 2001-08-30 2003-03-05 Noxxon Pharma AG Verfahren zur Markierung von L-Nukleinsäuren
US6942972B2 (en) * 2001-10-24 2005-09-13 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
EP1306382A1 (de) * 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
SI1572095T1 (sl) 2002-09-13 2015-12-31 Novartis Ag Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5158880A (en) * 1988-09-23 1992-10-27 E. I. Du Pont De Nemours And Company Process for preparing solid perfluorocarbon polymer supports having attached perfluorocarbon-substituted ligand or binder
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512978A (ja) * 2001-10-26 2005-05-12 ノクゾン ファルマ アーゲー 修飾l−核酸

Also Published As

Publication number Publication date
EP0691981A1 (de) 1996-01-17
WO1994020523A1 (en) 1994-09-15
AU6402594A (en) 1994-09-26
CA2157902A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
JP3170235B2 (ja) 修飾ヌクレオチド
US5633360A (en) Oligonucleotide analogs capable of passive cell membrane permeation
JP3186795B2 (ja) 末端3′−3′または5′−5′ヌクレオチド間結合を有するオリゴヌクレオチド類似体
JP3293820B2 (ja) 標的ポリヌクレオチドにハイブリツド形成するための新規な一工程方法とポリヌクレオチド化合物
JP4624104B2 (ja) オリゴヌクレオチド結合体
JPH08503854A (ja) 抗体のオリゴヌクレオチド複合体およびキレート化された放射性ヌクレオチドの相補的オリゴヌクレオチド複合体を用いる腫瘍部位の逐次ターゲッティング
DE69129127T2 (de) Zielgesuchte radioaktive immunoreagenzien
WO1994020523A1 (en) Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
JP3143506B2 (ja) 治療用物質の標的送達用医薬組成物
JPH07506667A (ja) 錯化剤並びに治療及び診断用組成物及び方法に有用な標的化免疫試薬
JP4854913B2 (ja) オリゴヌクレオチド結合体
US20070010014A1 (en) Compositions and methods for enhanced delivery to target sites
JP2009197024A (ja) 金属複合体及びオリゴヌクレオチドから作られた接合体、該接合体を含む薬剤、放射線診断におけるそれらの使用並びにそれらの製造のための方法
EA010687B1 (ru) Гуманизированное антитело
US20020077306A1 (en) Conjugates made of metal complexes and oligonucleotides, agents containing the conjugates, their use in radiodiagnosis as well as process for their production
AU5984094A (en) Immunoreactive reagents employing dihydrofolate reductase
EP0613379B1 (de) Therapeutische Mittel
US20210290787A1 (en) Macrocycle conjugates
Giglio et al. Synthesis and initial evaluation of radioactive 5-I-α-methyl-tryptophan: a Trp based agent targeting IDO-1
JPH09501147A (ja) モノアミンオキシダーゼを使用する免疫反応性試薬
JP2002503671A (ja) O6−ベンジルグアニン含有オリゴデオキシリボヌクレオチドおよびその使用
KR20150045592A (ko) 다양한 압타머에 적용 가능한 방사성동위원소 표지된 핵산 구조체 개발 및 표지방법
CA2154896A1 (en) Immunoreactive reagents employing heterodimers
US7713528B1 (en) Method for in vivo delivery of active compounds using reagent conjugate
US20070009435A1 (en) Compositions and methods for enhanced delivery to target sites